[1] TIAN C, LI Y, CHEN Z C.A retrospective analysis of primary gastrointestinal non-Hodgkin lymphomas:clinical features, prognostic factors and treatment outcomes[J]. Onco Targets Ther, 2020, 13:5345-5352.
[2] WANG Y G, ZHAO L Y, LIU C Q, et al. Clinical characteristics and prognostic factors of primary gastric lymphoma[J]. Medicine, 2016, 95(31):e4250.
[3] KURUCU N, AKYVZ C, YALÇIN B, et al. Primary gastric lymphoma:a report of 16 pediatric cases treated at a single institute and review of the literature[J]. Pediatr Hematol Oncol, 2020, 37(8):656-664.
[4] LI M R, ZHANG S H, GU F, et al. Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma:a 22-year experience from South China[J]. Int J Clin Exp Pathol, 2014, 7(5):2718-2728.
[5] MALIPATEL R, PATIL M, PRITILATA ROUT P, et al. Primary gastric lymphoma:clinicopathological profile[J]. Euroasian J Hepatogastroenterol, 2018, 8(1):6-10.
[6] SHANNON E M, MACQUEEN I T, MILLER J M, et al. Management of primary gastrointestinal non-Hodgkin lymphomas:a population-based survival analysis[J]. J Gastrointest Surg, 2016, 20(6):1141-1149.
[7] National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology.B-Cell lymphoma.Version 4.2020[EB/0L]. https://www.nccn.org.
[8] AGUSTIN A, NAMBO M J S, NERI N, et al. The role of surgery in primary gastric lymphoma[J]. Ann Surg, 2004, 240(1):44-50.
[9] SELÇUKBIRICIK F, TURAL D, ELICIN O, et al. Primary gastric lymphoma:conservative treatment modality is not inferior to surgery for early-stage disease[J]. ISRN Oncology, 2012, 2012:1-6.
[10] O'MALLEY D P, GOLDSTEIN N S, BANKS P M.The recognition and classification of lymphoproliferative disorders of the gut[J]. Hum Pathol, 2014, 45(5):899-916.
[11] LIN J L, LI P, XIE J W, et al. Impact of surgery on long-term survival of patients with primary gastric diffuse large B-cell lymphoma:a SEER population-based study[J]. Gastroenterol Res Pract, 2019, 2019:9683298.
[12] POESCHEL V, HELD G, ZIEPERT M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER):a randomised, phase 3, non-inferiority trial[J]. Lancet, 2019, 394(10216):2271-2281.
[13] PROUET P, GIRI S, WIEDOWER E, et al. Addition of rituximab to chemotherapy reduced the rate of surgery for gastric-DLBCL without increasing early mortality[J]. Anticancer Res, 2017, 37(2):813-818.
[14] TANAKA T, SHIMADA K, YAMAMOTO K, et al. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era:a multicenter study of 95 patients in Japan[J]. Ann Hematol, 2011, 91(3):383-390.
[15] SOHN B S, KIM S M, YOON D H, et al. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma[J]. Ann Hematol, 2012, 91(11):1731-1739.
[16] YANG H, WU M, SHEN Y, et al. Treatment strategies and prognostic factors of primary gastric diffuse large B cell lymphoma:a retrospective multicenter study of 272 cases from the China Lymphoma Patient Registry[J]. Int J Med Sci, 2019, 16(7):1023-1031.
[17] APOSTOLIDIS J, SAYYED A, DARWEESH M, et al. Current clinical applications and future perspectives of immune checkpoint inhibitors in non-Hodgkin lymphoma[J]. J Immunol Res, 2020, 2020:1-18.
[18] 曾辉, 王进峰, 尚松, 等. PD-L1和BAFF-R在胃弥漫性大B细胞淋巴瘤中的表达及其临床意义[J]. 中国现代手术学杂志, 2019, 23(1):1-6.
[19] WANG Y, WU L, TIAN C, et al. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas[J]. Ann Hematol, 2018, 97(2):229-237.
[20] SMITH S D, TILL B G, SHADMAN M S, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma:potential for biomarker driven therapy[J]. Br J Haematol, 2020, 189(6):1119-1126.
[21] NASTOUPIL L J J M, FENG L, SPIEGEL J Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma:results from the US Lymphoma CAR T Consortium[J]. J Clin Oncol, 2020, 38(27):3119-3128.
[22] DE MIGUEL M, CALVO E.Clinical challenges of immune checkpoint inhibitors[J]. Cancer Cell, 2020, 38(3):326-333.
[23] PERSKY D O, UNGER J M, SPIER C M, et al. Phase Ⅱ study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma:Southwest Oncology Group Study 0014[J]. J Clin Oncol, 2008, 26(14):2258-2263.
[24] BERTOLINI F, KANG H J, LEE H H, et al. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy[J]. PLoS One, 2020, 15(9):e0238807.
[25] ARIGA H, LI Q, LI W, et al. Consolidation radiotherapy in stage IE-IIE, non-Bulky primary gastric diffuse large B-cell lymphoma with post-chemotherapy complete remission[J]. PLoS One, 2015, 10(7):e0133469.
[26] MISHIMA Y T Y, YOKOYAMA M, NISHIMURA N, et al. R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma[J]. Exp Hematol Oncol, 2012, 24(1):30.
[27] KELSEY C R, BROADWATER G, JAMES O, et al. Phase 2 study of dose-reduced consolidation radiation therapy in diffuse large B-cell lymphoma[J]. Int J Radiat Oncol Biol Phys, 2019, 105(1):96-101.
[28] BERGER M D, TRELLE S, BVCHI A E, et al. Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma:a comprehensive meta-analysis[J]. Haematologica, 2021, 106(7):1923-1931.
[29] BOBILLO S J E, LAVERY J A, SERMER D, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B cell lymphoma in the Rituximab-Era[J]. Blood, 2020, 137(1):39-48.
[30] VITOLO U, SEYMOUR J F, MARTELLI M, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2016, 27:91-102.
[31] COUTO M E, OLIVEIRA I, DOMINGUES N, et al. Gastric diffuse large B-cell lymphoma:a single-center 9-year experience[J]. Indian J Hematol Blood Transfus, 2021, 37(3):1-5.
[32] TSAI H J T J, CHEN L T, WU M S, et al. A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue[J]. Haematologica, 2020, 105(7):349-354.
[33] KUO S H, YEH K H, CHEN L T, et al. Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach:a distinct entity with lower aggressiveness and higher chemosensitivity[J]. Blood Cancer J, 2014, 4(6):220.
[34] NAKAMURA S, SUGIYAMA T, MATSUMOTO T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication ofHelicobacter pylori:a multicentre cohort follow-up study of 420 patients in Japan[J]. Gut, 2012, 61(4):507-513.
[35] ZUCCA E, ARCAINI L, BUSKE C, et al. Marginal zone lymphomas:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(1):17-29.
[36] SUGIZAKI K, TARI A, KITADAI Y, et al. Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma:a prospective, nationwide, multicenter study in Japan[J]. Helicobacter, 2018, 23(2):e12474.
[37] MATYSIAK-BUDNIK T, JAMET P, RUSKONÉ-FOURMESTRAUX A, et al. Gastric MALT lymphoma in a population-based study in France:clinical features, treatments and survival[J]. Aliment Pharmacol Ther, 2019, 50(6):654-663.
[38] PARK B S, LEE S H.Clinical efficacy of radiotherapy in helicobacter pylori negative or unresponsive to eradication therapy primary gastric mucosa-associated lymphoid tissue lymphoma[J]. Korean J Gastroenterol, 2019, 73(1):19-25.
[39] OHKUBO Y, SAITO Y, USHIJIMA H, et al. Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma:long-term outcomes over 10 years[J]. J Radiat Res, 2017, 58(4):537-542.
[40] PINNIX C C, GUNTHER J R, MILGROM S A, et al. Outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue(MALT) lymphoma[J]. Int J Radiat Oncol Biol Phys, 2019, 104(2):447-455.
[41] SCHMELZ R M S, THIEDE C, BRUECKNER S, et al. Sequential pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages ⅠE & Ⅱ1E:a prospective randomized trial[J]. J Gastroenterol, 2019, 54(5):388-395.
[42] THIEBLEMONT C, ZUCCA E.Clinical aspects and therapy of gastrointestinal MALT lymphoma[J]. Best Pract Res Clin Haematol, 2017, 30(1-2):109-117.
[43] VIOLETA FILIP P, CUCIUREANU D, SORINA DIACONU L, et al. MALT lymphoma:epidemiology, clinical diagnosis and treatment[J]. J Med Life, 2018, 11(3):187-193. |
